In contrast, CHEK1 and PLK1 are cell cycle regulators (51, 52), whose high expression is associated with enhanced tumor cell proliferation (52), offering a molecular explanation for the poorer prognosis and potentially reduced responsiveness to conventional immunotherapies in the high-risk group. The gene discussed is CHEK1; the disease is neoplasm.